Table 5.

Neurologic diseases treated with both intravenous immunoglobulin infusion and therapeutic plasma exchange

Neurologic Disease	Role of intravenous immunoglobulin infusion in treatment [33]	Role of therapeutic plasma exchange in treatment [13]
Acute inflammatory demyelinating polyneuropathy (AIDP, Guillain-Barré syndrome)	Definite	First line therapy with a strong recommendation and high-quality evidence. (Category I, Recommendation grade 1A)
Chronic inflammatory demyelinating polyneuropathy (CIDP)	Definite	First line therapy with a strong recommendation and moderate quality evidence. (Category I, Recommendation grade 1B)
Lambert-Eaton myasthenic syndrome (LEMS)	Probable	Second line therapy with a weak recommendation and low quality or very low quality evidence. (Category II, Recommendation grade 2C)
IgM anti-myelin associated glycoprotein paraprotein associated peripheral neuropathy	Probable	First line therapy with a strong recommendation and low quality or very low quality evidence. (Category I, Recommendation grade 1C)
Myasthenia gravis (MG)	Probable	First line therapy with a strong recommendation and high-quality evidence. (Category I, Recommendation grade 1A)
Multiple sclerosis (MS)	Possible	Second line therapy with a strong recommendation and moderate quality evidence. (Category II, Recommendation grade 1B)
Acute disseminated encephalomyelitis (ADEM)	Possible	Second line therapy with a weak recommendation and moderate quality evidence. (Category II, Recommendation grade 2C)